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Introduction: The safety, efficacy and prolonged half-life of recombinant factor VIII Fc fusion protein (rFVIIIFc)
in previously treated patients with severe haemophilia A was demonstrated in the phase 3 A-LONG and Kids A-
LONG studies. Here, we report interim safety and efficacy data from the rFVIIIFc extension study, ASPIRE
(ClinicalTrials.gov #NCT01454739). Methods: Eligible subjects could enrol in ASPIRE upon completing A-
LONG or Kids A-LONG. There were four treatment groups: individualized prophylaxis; weekly prophylaxis;
modified prophylaxis (for subjects in whom optimal treatment could not be achieved with individualized or
weekly prophylaxis); and episodic treatment. The primary endpoint was development of inhibitors. Results:
A total of 150 A-LONG subjects and 61 Kids A-LONG subjects enrolled in ASPIRE. As of the interim data cut
(6 January 2014), the median time on study was 80.9 (A-LONG) and 23.9 (Kids A-LONG) weeks. The majority
of subjects (A-LONG, 92.0%; Kids A-LONG, 57.4%) had ≥100 cumulative rFVIIIFc exposure days. No
inhibitors were observed. Adverse events were generally consistent with those expected in the general
haemophilia A population. Median annualized bleeding rates (ABRs) were low with individualized [A-LONG:
0.66; Kids A-LONG: 0.00 (<6 years old), 1.54 (6 to <12 years old)], weekly (A-LONG: 2.03) and modified (A-
LONG: 1.97) prophylaxis. There was no change in prophylactic infusion frequency or total weekly prophylactic
dose in the majority of subjects from A-LONG and Kids A-LONG. Conclusion: Interim data from ASPIRE
confirm the long-term safety of rFVIIIFc and the maintenance of a low ABR with extended-interval prophylactic
dosing in patients with severe haemophilia A.
Keywords: factor VIII, haemophilia A, phase 3, prophylaxis, recombinant fusion proteins
Introduction
Patients with haemophilia A are at risk for serious
complications, including life-threatening spontaneous
and traumatic bleeding and recurrent haemarthroses
[1]. Prophylactic treatment with coagulation factor
VIII (FVIII) is the standard of care to prevent bleeding
in patients with haemophilia A. Optimal prophylaxis
with conventional FVIII products, which have half-
lives of approximately 12 h, often requires three to
four intravenous infusions weekly [2,3]; more frequent
administration may be necessary in children, who gen-
erally have a shorter FVIII half-life compared with
adults [4]. Such frequent infusions can deter adherence
to prophylaxis [5–7].
Recombinant FVIII Fc fusion protein (rFVIIIFc) was
developed to prolong the half-life of FVIII [8–11]. The
Fc portion of rFVIIIFc binds to the neonatal Fc recep-
tor and utilizes the IgG recycling pathway to extend
the plasma half-life of the molecule [12]. The safety,
efficacy and prolonged half-life of rFVIIIFc were dem-
onstrated in previously treated adults, adolescents and
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children with severe haemophilia A in the phase 3 A-
LONG and Kids A-LONG studies [13,14]. Here, we
report interim data from subjects enrolled in the
rFVIIIFc extension study, ASPIRE (ClinicalTrials.gov
identifier, NCT01454739), the aim of which was to
evaluate the long-term safety of rFVIIIFc and its effi-
cacy in the prevention and treatment of bleeding epi-
sodes in subjects with haemophilia A.
Materials and methods
Study design
Subjects completing the A-LONG [13] or Kids A-
LONG [14] studies were eligible for enrolment in
ASPIRE. The data cut-off date for this interim analysis
was 6 January 2014; the estimated study completion
date is December 2018. This open-label, non-random-
ized study had an episodic (on-demand) treatment
group and three prophylactic treatment groups: indi-
vidualized, weekly and modified prophylaxis. In the
episodic group, dosing was based on the type and
severity of bleeding episodes. Subjects in the individu-
alized prophylaxis group were treated with 25–
65 IU kg1 rFVIIIFc every 3–5 days, or twice-weekly
rFVIIIFc (20–65 IU kg1 on Day 1, 40–65 IU kg1 on
Day 4). In subjects <12 years of age, the investigator
could make dose adjustments up to a maximum of
80 IU kg1, with an administration frequency of up
to every 2 days, if necessary, to maintain adequate
FVIII activity trough levels and prevent spontaneous
bleeding episodes. The weekly prophylaxis group
received 65 IU kg1 rFVIIIFc every 7 days. Subjects in
whom optimal treatment could not be achieved using
either the individualized or weekly prophylaxis dosing
guidelines could participate in the modified prophy-
laxis group (Data S1).
Subjects were permitted to change their treatment
group at the time of enrolment or at any time during
the extension study. Subjects <12 years of age were
allowed to participate only in the individualized and
modified prophylaxis groups; however, a Kids A-
LONG subject who reached 12 years of age during
the study could choose to participate in any of the
four treatment groups.
Outcome measures
The primary endpoint was development of inhibitors
(anti-FVIII neutralizing antibodies). Subjects were
tested for inhibitor formation at each clinic visit
(approximately every 6 months). A positive inhibitor
test result was defined as a neutralizing antibody value
≥0.6 BU mL1 (by Nijmegen-modified Bethesda assay)
and confirmed on retesting within 2–4 weeks. Second-
ary endpoints included the annualized number of
bleeding episodes per subject, rFVIIIFc exposure days
(EDs), and subject’s assessment of response to treat-
ment of a bleeding episode (Data S1). Additional out-
comes included the incidence of adverse events (AEs),
the number of infusions and dose per infusion
required to control a bleeding episode and the assess-
ment of haemostatic response in subjects undergoing
major surgery.
Analytical methods
Exposure and efficacy analyses were performed sepa-
rately for subjects from A-LONG and Kids A-LONG.
Results were analysed by treatment group for all sub-
jects; Kids A-LONG subjects were also analysed by
age cohort (<6 years of age; 6 to <12 years of age) at
the time of entry into the parent study. Subjects who
changed treatment groups were included in the sum-
mary analyses of any group in which they participated
for the period of time that they were in the given
group.
Safety analyses were performed on data from sub-
jects who received at least one dose of rFVIIIFc. Effi-
cacy analyses were performed on data from subjects
who participated in the episodic group at any time, or
who had ≥2 prophylactic infusions of rFVIIIFc (exclu-
sive of perioperative management periods).
Results
Study population
The study enrolled 211 male subjects: 150/153 subjects
(98.0%) who completed A-LONG and 61/67 subjects
(91.0%) who completed Kids A-LONG (<6 years of
age, n = 30; 6 to <12 years of age, n = 31; Fig. 1, Table
S1). As of the interim data cut, 10 subjects from A-
LONG and no subjects from Kids A-LONG had discon-
tinued the extension study (Fig. 1).
At the time of the interim data cut, the median time
on ASPIRE among subjects from A-LONG was
80.9 weeks; 121 subjects (80.7%) had completed an
18-month study visit. From the start of A-LONG to
the ASPIRE interim data cut, subjects had a median of
111.7 cumulative weeks of rFVIIIFc treatment [137
subjects (91.3%) had received rFVIIIFc for ≥2 years],
and a median 193.5 cumulative rFVIIIFc EDs [138
subjects (92.0%) had ≥100 EDs] (Figure S1).
Among Kids A-LONG subjects, the median time on
ASPIRE was 23.9 weeks (<6 years cohort, 10.6 weeks;
6 to <12 years cohort, 28.7 weeks). At the time of the
interim data cut, 22 subjects (36.1%) had completed
the 6-month study visit. From the start of Kids A-
LONG to the ASPIRE interim data cut, subjects had a
median of 51.1 cumulative weeks of rFVIIIFc treatment
[23 subjects (37.7%) had received rFVIIIFc for
≥1 year], and a median 103.0 cumulative rFVIIIFc EDs
[35 subjects (57.4%) had ≥100 EDs] (Figure S1).
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Safety summary
No subjects developed an inhibitor to FVIII during the
ASPIRE study as of the interim data cut. AEs were
generally consistent with those expected in the general
haemophilia population (Table 1). The majority of
AEs were judged by the investigator to be unrelated to
rFVIIIFc treatment.
Three adult subjects (1.4%) experienced a total of
four non-serious, mild AEs that were assessed by the
investigator as related to rFVIIIFc treatment. One
subject retrospectively reported chromaturia (inter-
mittent dark urine) with the first morning void 24 h
after a dose of rFVIIIFc, occurring three times over
~1.5 years, and also noted after taking other medica-
tions. One subject reported headache and hot flush
[hot flashes] occurring on a single day only. The
events of chromaturia, headache and hot flush each
resolved spontaneously without treatment, and did
not recur despite continued rFVIIIFc treatment in
the study. One additional subject receiving episodic
treatment was reported to have elevated blood
creatinine (128 lmol L1 at final study visit; refer-
ence range: 67–112 lmol L1) observed 12 days
after receiving his most recent dose of rFVIIIFc. The
event of increased blood creatinine was reported to
result in discontinuation of rFVIIIFc treatment and
withdrawal from the study. The subject had multiple
factors that may have contributed to the event,
including medical history of kidney stones, hyperten-
sion, and HIV, and concomitant medications known
to be associated with renal impairment (hydrochloro-
thiazide, Lisinopril, and tenofovir disoproxil fuma-
rate).
A total of 29 serious AEs (SAEs) were reported on
study, excluding perioperative management periods
(Table S2), with 23 subjects (10.9%) experiencing at
least one SAE (four subjects experienced two SAEs
each, and one subject experienced three SAEs). All of
the SAEs were assessed by the investigator as unre-
lated to rFVIIIFc treatment, all had resolved by the
time of the interim data cut, and none led to study
discontinuation. There were no reports of serious
*Subjects remained in their parent study-assigned age cohorts throughout the extension study. 
†Discontinued due to physician decision: noncompliance with dosing and use of the electronic patient diary (n = 1); use of nonstudy FVIII under non-emergency 
circumstances (n = 1). 
‡Discontinued due to protocol violation: noncompliance with prophylactic dosing (n = 1); use of nonstudy FVIII under non-emergency circumstances (n = 1). 
^Discontinued for reasons of “Other”: inability to participate due to incarceration (n = 1); inability to comply with the demands of the study (n = 1). 
Fig. 1. Subject disposition. Subjects who completed the phase 3 A-LONG and Kids A-LONG studies were eligible for enrolment in the ASPIRE extension
study. Of the subjects completing the phase 3 studies, 150/153 A-LONG subjects (98.0%) and 61/67 (91.0%) Kids A-LONG subjects respectively enrolled in
ASPIRE. Ten subjects from A-LONG discontinued the extension study early; no subjects from Kids A-LONG discontinued the study as of the interim data
cut.
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allergic reactions or anaphylaxis to rFVIIIFc, no seri-
ous vascular thrombotic events, and no deaths.
Changes to prophylactic dosing regimen
The protocol permitted subjects to change treatment
groups at any time during the extension study. Of the
150 A-LONG subjects enrolled in ASPIRE, 25
(16.7%) changed treatment groups at the time of en-
rolment and 17 (11.3%) made one change to their
treatment group during ASPIRE; no subjects changed
treatment groups more than once (Fig. 2). Nearly all
Kids A-LONG subjects (59/61 subjects; 96.7%) con-
tinued on individualized prophylaxis; two subjects
switched to the modified prophylaxis group upon en-
rolment into ASPIRE. No Kids A-LONG subjects
changed their treatment group during ASPIRE. A sum-
mary of subjects in the modified prophylaxis group is
provided in Data S1.
The majority of subjects previously on a prophylac-
tic regimen in A-LONG had either no change to their
infusion interval (92/128 subjects; 71.9%) or had a
longer infusion interval (28/128 subjects; 21.9%) dur-
ing ASPIRE (Fig. 3). Of the 19 subjects randomized to
the once-weekly treatment arm of A-LONG (who had
been previously treated episodically with FVIII), only
three subjects changed to a shorter prophylactic infu-
sion interval (twice-weekly) during ASPIRE. The pro-
portion of A-LONG subjects with a prophylactic
infusion interval of 5 days or longer remained consis-
tent in the extension study (at the end of A-LONG,
43.8%; during ASPIRE, 43.3%). No A-LONG sub-
jects switched from prophylactic to episodic treatment
in ASPIRE. However, 15/22 subjects (68.2%) from
the episodic arm of A-LONG switched to a prophy-
laxis group in ASPIRE (individualized, n = 8; weekly,
n = 5; modified, n = 2). The majority of Kids A-
LONG subjects (58/61 subjects; 95.1%) had no
change to their prophylactic infusion interval on
ASPIRE (Figure S2). Among subjects infusing twice-
weekly in Kids A-LONG, 53/56 subjects (94.6%)
remained on a twice-weekly dosing schedule in
ASPIRE; two subjects lengthened their prophylactic
infusion interval to either every 4 or every 5 days.
rFVIIIFc total weekly prophylactic dose
The total weekly prophylactic dose remained generally
consistent among A-LONG and Kids A-LONG sub-
jects during the extension study. For A-LONG sub-
jects, the median [interquartile range (IQR)] average
total weekly prophylactic dose in the individualized,
weekly and modified prophylaxis groups was 79.6
(74.5, 97.1) IU kg1, 65.4 (62.8, 67.4) IU kg1 and
69.5 (64.3, 89.3) IU kg1 respectively. Median annu-
alized rFVIIIFc consumption was 4181.3, 3500.6 and
3724.6 IU kg1, for the respective prophylactic
groups. Among A-LONG subjects previously treated
prophylactically (n = 128), 64.1% had no change to,
20.3% reduced, and 15.6% increased their total
weekly prophylactic dose (Fig. 4a). The median (IQR)
average weekly prophylactic dose in Kids A-LONG
subjects receiving individualized prophylaxis was 99.9
(88.6, 114.2) IU kg1 for subjects <6 years of age
(median annualized consumption = 5133.1 IU kg1),
and 91.2 (81.0, 107.9) IU kg1 for subjects 6 to
<12 years of age (median annualized consump-
tion = 4819.8 IU kg1). Compared with their previous
total weekly prophylactic dose, 78.7% had no change
to, 11.5% reduced, and 9.8% increased their total
weekly prophylactic dose (Fig. 4b).
Annualized bleeding rate
In the individualized, weekly and modified prophy-
laxis groups in ASPIRE, 38.9%, 22.2% and 23.5% of
Table 1. AE summary (≥3% in either study population).
Parent study
Overall
N = 211
A-LONG
N = 150
Kids A-LONG
N = 61
Subjects with at
least one AE, n (%)*,†
111 (74.0) 27 (44.3) 138 (65.4)
Nasopharyngitis 24 (16.0) 3 (4.9) 27 (12.8)
Upper respiratory
tract infection
13 (8.7) 3 (4.9) 16 (7.6)
Arthralgia 11 (7.3) 0 11 (5.2)
Fall 7 (4.7) 3 (4.9) 10 (4.7)
Laceration 8 (5.3) 0 8 (3.8)
Diarrhoea 7 (4.7) 1 (1.6) 8 (3.8)
Headache 7 (4.7) 0 7 (3.3)
Cough 6 (4.0) 1 (1.6) 7 (3.3)
Influenza 6 (4.0) 1 (1.6) 7 (3.3)
Contusion 5 (3.3) 0 5 (2.4)
Dental caries 5 (3.3) 0 5 (2.4)
Haemophilic arthropathy 5 (3.3) 0 5 (2.4)
Viral infection 2 (1.3) 3 (4.9) 5 (2.4)
Vomiting 2 (1.3) 3 (4.9) 5 (2.4)
Head injury 2 (1.3) 2 (3.3) 4 (1.9)
Central venous
catheter removal
0 2 (3.3) 2 (0.9)
Viral upper respiratory tract 0 2 (3.3) 2 (0.9)
Tooth socket haemorrhage 0 2 (3.3) 2 (0.9)
Number of subjects who
experienced at least
one SAE, n (%)
17 (11.3) 6 (9.8) 23 (10.9)
Total number of SAE, n 22 7 29
AE, adverse event; SAE, serious AE; rFVIIIFc, recombinant factor VIII Fc
fusion protein.
*Excludes AEs occurring during the perioperative management period;
percentages are based on the number of subjects treated with rFVIIIFc.
All but four AEs occurring in three adult subjects were judged by the
investigator to be unrelated to rFVIIIFc treatment. Among 15 subjects in
the surgical subgroup, 7 subjects (46.7%) experienced at least one AE
during the perioperative management period with a total of 14 AEs
reported (13 non-serious AEs; 1 SAE); all 14 AEs were assessed by inves-
tigators as unrelated to rFVIIIFc.
†Ten subjects experienced at least one AE (14 total AEs) that had an
event onset prior to Day 1 of the extension study; these AEs were
reported in the clinical database for ASPIRE instead of the clinical data-
bases for A-LONG or Kids A-LONG; this had no impact on the overall
safety profile of rFVIIIFc.
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A-LONG subjects, respectively, experienced zero
bleeding episodes on study. Median (IQR) bleeding
rates in ASPIRE were low in subjects in the rFVIIIFc
prophylaxis groups compared with subjects in the epi-
sodic group (Table 2). Annualized bleeding rates
(ABRs) in subjects with an efficacy period of
≥6 months in a given treatment group were consistent
with ABRs in the overall population. In all A-LONG
subjects treated with rFVIIIFc prophylaxis during
ASPIRE, the median ABR for spontaneous joint bleed-
ing episodes was 0.0, compared with 11.2 for subjects
treated episodically. In subjects with ≥1 target joint
present at baseline, the median (IQR) ABR was 0.7
(0.0, 3.0) in the individualized prophylaxis group
(n = 72), 2.5 (0.6, 4.5) in the weekly prophylaxis
group (n = 16), 4.4 (1.3, 9.6) in the modified prophy-
laxis group (n = 12) and 15.2 (5.2, 33.2) in the epi-
sodic treatment group (n = 12).
Among Kids A-LONG subjects in the individualized
and modified prophylaxis groups during ASPIRE,
59.3% and 50.0% of subjects respectively experienced
zero bleeding episodes on study. The median (IQR)
ABR in Kids A-LONG subjects is presented in
Table 3. The median ABR for spontaneous joint
bleeding episodes was 0.0 in both age cohorts. Among
Kids A-LONG subjects in the individualized prophy-
laxis group who had ≥1 target joint present at base-
line, the median (IQR) ABR was 4.4 (0.0, 8.8) for
those <6 years of age (n = 2) and 1.8 (0.0, 3.4) for
those 6 to <12 years of age (n = 5).
Treatment of a bleeding episode
A total of 566 bleeding episodes occurred among
A-LONG subjects who were treated prophylactically on
ASPIRE; subjects treated episodically experienced a total
of 262 bleeding episodes (Table 4, Table S3). Overall,
90.8% of bleeding episodes were controlled with one
infusion; 96.9% with one or two infusions. Among first
infusions evaluated by subjects for a response, 83.8%
overall were rated as excellent or good (individualized
prophylaxis, 77.6%; weekly prophylaxis, 80.9%; modi-
*Subjects enrolled in ASPIRE included 109 of the 112 subjects who completed A-LONG in the individualized prophylaxis arm, and 19/19 and 22/22 subjects completing A-
LONG in the weekly prophylaxis and episodic treatment arms, respectively.  
†Five subjects who continued episodic treatment from the end of A-LONG to the beginning of ASPIRE moved into a different treatment group within the first week of the 
study (individualized prophylaxis, n = 3; modified prophylaxis, n = 2). The 2 subjects who moved from the episodic group into the modified prophylaxis group did not have a 
defined routine prophylaxis regimen in the modified prophylaxis group. 
‡Protocol permitted subjects to change treatment groups over the course of this extension study; therefore, subjects may be represented in more than 1 group. “Total” 
indicates the number of subjects in the given group at any time from the beginning of ASPIRE to the interim data cut.  
^One subject from A-LONG was not assessed for efficacy because he had surgery prior to the extension study and was in his surgical period from the time of enrolment until 
after the interim data cut.  
A-LONG
Treatment arm*
ASPIRE
Treatment group 
at interim data cut
ASPIRE
Total in group
(at any me)‡
ASPIRE
Starng treatment group
Fig. 2. Change in treatment group among adults and adolescents (end of A-LONG to ASPIRE interim data cut). Subjects’ treatment groups at the end of A-
LONG (leftmost boxes), at the start of ASPIRE (middle boxes), and at the interim data cut for ASPIRE (rightmost boxes) are shown. Subjects in the individu-
alized prophylaxis group were treated with 25–65 IU kg1 recombinant factor VIII Fc fusion protein (rFVIIIFc) every 3–5 days, or twice-weekly rFVIIIFc
(20–65 IU kg1 on Day 1, 40–65 IU kg1 on Day 4). Subjects in the weekly prophylaxis group received 65 IU kg1 at weekly intervals. In the modified pro-
phylaxis group, dosing could be adjusted to meet the needs of individual subjects; this included, but was not limited to, less frequent dosing, addition of ‘pre-
vention’ doses prior to strenuous activity, or targeting a FVIII trough level of >3% (if the bleeding history and/or activity level required). Of the 150 A-LONG
subjects enrolled in ASPIRE, 42 (28.0%) changed treatment groups upon enrolment into or during ASPIRE, including 15/22 subjects treated episodically in
A-LONG who changed to a prophylactic regimen in ASPIRE; no subjects changed treatment groups more than once. Subjects who changed groups during the
study were included in the safety and efficacy analyses for any treatment group in which they participated, for the period of time they participated in that
group, as indicated at the right of the figure.
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ASPIRE infusion frequency (interim data cut)
A-LONG 
infusion frequency
(end of study)
Every
3 days
N = 28 
(18.7%)
Twice
weekly
N = 43
(28.7%)
Every
4 days
N = 9
(6.0%)
Every 
5 days
N = 26
(17.3%)
Every 
6 days
N = 2
(1.3%)
Once
Weekly
Every
3 days
Twice
weekly
Every
4 days
Every
5 days
Every
6 days
Once
Weekly
N = 33 
(22%)
Every 3 days
N = 35 (23.3%) 26 6 3 0 0 0
Twice weekly
N = 33 (22.0%) 0 26 2 3 0 2
Every 4 days 
N = 4 (2.7%) 1 1 2 0 0 0
Every 5 days
N = 37 (24.7%) 0 1 2 22 2 10
-- -- -- -- -- --
Once weekly*
N = 19 (12.7%) 0 3 0 0 0 16
Other
N = 2 
(1.3%)
Episodic
N = 7 
(4.7%)
Episodic treatment
N = 22 (14.7%) 1 6 0 1 0 5 2
† 7
Change in 
infusion interval 
Shortened 
(n = 8, 6.3%) 
No change 
(n = 92, 71.9%) 
Lengthened 
(n = 28, 21.9%) 
*Subjects in the weekly prophylaxis group of A-LONG were previously on FVIII episodic treatment and were randomised into this group vs. the episodic treatment group. 
†These 2 subjects were treated episodically during A-LONG and moved to the modified prophylaxis group during ASPIRE; they did not have a defined routine 
prophylaxis regimen during ASPIRE. 
Fig. 3. Change in infusion frequency among adult and adolescent subjects (end of A-LONG to ASPIRE interim data cut). Changes in prophylactic infusion
frequency from the end of A-LONG to the time of the ASPIRE interim data cut are shown for individual A-LONG subjects (n = 128). The majority of these
subjects had either no change to (white boxes) or lengthened (dark grey boxes) their infusion interval during ASPIRE. The infusion frequency at the time of
the ASPIRE interim data cut is also shown for subjects previously in the episodic arm of A-LONG (n = 22).
Change in total weekly prophylactic dose,  IU kg–1
(end of A-LONG to ASPIRE interim data cut)
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Change in total weekly prophylactic dose,  IU kg–1
(end of Kids A-LONG to ASPIRE interim data cut)
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Kids A-LONG subjects (n = 61)(a) (b)
Fig. 4. Change in total weekly prophylactic dose during ASPIRE among subjects treated prophylactically in A-LONG and Kids A-LONG. Overall, the
majority of A-LONG (64.1%) and Kids A-LONG (78.7%) subjects had no change in their total weekly prophylactic dose during the extension study relative
to their total weekly prophylactic dose at the end of the parent study. The median change in weekly prophylactic dose was 0.0 IU kg1 week1. Among
A-LONG subjects, 20.3% reduced and 15.6% increased their total weekly prophylactic dose on ASPIRE. Among Kids A-LONG subjects, 11.5% reduced
and 9.8% increased their total weekly prophylactic dose on ASPIRE.
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fied prophylaxis, 87.6%; episodic treatment, 90.8%).
Among Kids A-LONG subjects, there were a total of
23 bleeding episodes in the <6 years of age cohort and
28 bleeding episodes in the 6 to <12 years of age
cohort. Of these bleeding episodes, 82.6% (<6 years
cohort) and 82.1% (6 to <12 years cohort) were con-
trolled with one infusion; 95.7% and 89.3%, respec-
tively, with one or two infusions. Among first infusions
evaluated by subjects for a response, 91.3% (<6 years
cohort) and 92.6% (6 to <12 years cohort) were rated
as excellent or good.
Perioperative management
During ASPIRE, a total of 15 major surgeries were
performed in 13 subjects from A-LONG (Data S1); no
major surgeries were performed on study in subjects
from Kids A-LONG. No unique safety concerns
emerged during the perioperative period. Thirteen
major surgeries in 11 A-LONG subjects were assessed
for response; haemostasis was rated by the investiga-
tor/surgeon as excellent or good for all 13 major
surgeries, with intraoperative and postoperative blood
loss comparable to what would be expected for a sub-
ject who did not have haemophilia.
Discussion and conclusions
These interim data from ASPIRE confirm the long-
term safety and efficacy of rFVIIIFc for the prevention
Table 2. Summary of annualized bleeding rate [median (IQR)] during
ASPIRE among A-LONG subjects with an efficacy period.*
Treatment group
Individualized prophylaxis, n 108
Overall ABR 0.66 (0.00, 2.63)
Spontaneous ABR 0.00 (0.00, 1.23)
Spontaneous joint ABR 0.00 (0.00, 0.64)
Traumatic ABR 0.00 (0.00, 1.28)
Subjects in group ≥6 months, n 98
ABR 0.67 (0.00, 2.59)
Weekly prophylaxis, n 27
Overall ABR 2.03 (0.60, 4.39)
Spontaneous ABR 0.76 (0.00, 2.66)
Spontaneous joint ABR 0.00 (0.00, 2.66)
Traumatic ABR 0.66 (0.00, 1.94)
Subjects in group ≥6 months, n 27
ABR 2.03 (0.60, 4.39)
Modified prophylaxis, n† 17
Overall ABR 1.97 (0.96, 7.03)
Spontaneous ABR 0.96 (0.00, 5.51)
Spontaneous joint ABR 0.00 (0.00, 3.84)
Traumatic ABR 0.65 (0.00, 2.51)
Subjects in group ≥6 months, n 17
ABR 1.97 (0.96, 7.03)
Episodic, n 14
Overall ABR 18.36 (10.45, 30.46)
Spontaneous ABR 13.27 (1.39, 16.60)
Spontaneous joint ABR 11.15 (1.39, 15.11)
Traumatic ABR 2.36 (0.00, 9.05)
Subjects in group ≥6 months, n 8
ABR 18.36 (13.41, 26.29)
ABR, annualized bleeding rate; IQR, interquartile range; rFVIIIFc, recom-
binant factor VIII Fc fusion protein.
*The efficacy period reflects the sum of all intervals of time during which
subjects were treated with rFVIIIFc according to the treatment regimens
of the study, excluding perioperative management periods. One subject
from A-LONG was not assessed for efficacy because he had surgery prior
to the study and was in his surgical period from the time of enrolment
until after the interim data cut-off date.
†Two subjects in the modified prophylaxis group were treated episodically
during A-LONG, and did not have a defined routine prophylaxis regimen
during ASPIRE.
Table 3. Summary of annualized bleeding rate [median (IQR)] during
ASPIRE among Kids A-LONG subjects with an efficacy period.*
Treatment group <6 years cohort
6 to <12 years
cohort
Individualized prophylaxis, n 29 30
Overall ABR 0.00 (0.00, 2.00) 1.54 (0.00, 3.41)
Spontaneous ABR 0.00 (0.00, 0.00) 0.00 (0.00, 1.75)
Spontaneous joint ABR 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
Traumatic ABR 0.00 (0.00, 0.00) 0.00 (0.00, 1.82)
Subjects in group ≥6 months, n 4 17
ABR 2.37 (0.00, 9.21) 1.51 (0.00, 1.82)
Modified prophylaxis, n 1 1
Overall ABR 6.55† 0.00
Spontaneous ABR 6.55 0.00
Spontaneous joint ABR 6.55 0.00
Traumatic ABR 0.00 0.00
Subjects in group ≥6 months, n 0 0
ABR, annualized bleeding rates; IQR, interquartile range; rFVIIIFc,
recombinant factor VIII Fc fusion protein.
*The efficacy period reflects the sum of all intervals of time during which
subjects were treated with rFVIIIFc according to the treatment regimens
of the study, excluding perioperative management periods.
†Subject was on-study for 0.31 years, and experienced two spontaneous
joint bleeding episodes during that time.
Table 4. Dose of rFVIIIFc required to control a bleeding episode during
ASPIRE.
Number of subjects
who experienced a
bleeding episode, n
Number
of bleeding
episodes, n*
Average dose
per infusion,
IU kg1,
median (IQR)
A-LONG (N = 150)
Individualized
prophylaxis
66 301 46.88
(26.94, 51.49)
Weekly
prophylaxis
21 143 33.19
(26.67, 50.85)
Modified
prophylaxis
13 122 34.19
(29.47, 38.96)
Episodic 11 262 26.88
(25.00, 31.25)
Kids A-LONG (N = 61)
Individualized
prophylaxis
<6 years 8 21 43.86
(28.57, 72.82)
6 to <12 years 16 28 49.27
(37.49, 58.24)
Modified
prophylaxis
<6 years 1 2 57.47 (NA)
6 to <12 years 0 0 NA
rFVIIIFc, recombinant factor VIII Fc fusion protein; IQR, interquartile
range; NA, not applicable.
*This includes all bleeding episodes reported during the study. Average
dose per infusion could not be evaluated for three A-LONG subjects
(individualized prophylaxis, n = 2; modified prophylaxis, n = 1) for
whom information on the dose(s) administered to treat a bleeding episode
was incomplete.
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and treatment of bleeding in previously treated adults,
adolescents and children with severe haemophilia A.
This study represents the most extensive exposure to a
long-acting factor to date – the majority of subjects
had ≥100 EDs from the start of the parent study to
the ASPIRE interim data cut. As of the interim data
cut, no subjects developed an inhibitor during this
study, and the AEs observed were generally consistent
with those expected in the general haemophilia popu-
lation.
Although subjects were allowed to change treatment
groups during ASPIRE, only 28.0% and 3.3% of the
A-LONG and Kids A-LONG subjects, respectively,
switched groups upon enrolment or during the exten-
sion study; no one switched groups more than once.
In ASPIRE, the majority of subjects on rFVIIIFc pro-
phylaxis in the parent studies were able to maintain
or lengthen their infusion interval. For example,
among subjects who were infusing twice weekly at the
end of A-LONG, 79% stayed on a twice-weekly regi-
men in ASPIRE, while the remaining 21% extended
their dosing interval. Among subjects on weekly pro-
phylaxis in A-LONG (all of whom were treated epi-
sodically prior to A-LONG), 84% chose to remain on
this regimen in ASPIRE, suggesting weekly rFVIIIFc
dosing is a viable therapeutic option for a number of
subjects. While the median ABR in the weekly pro-
phylaxis group was higher than that of the individual-
ized prophylaxis group in ASPIRE (2.03 vs. 0.66), it
was lower than that observed in the weekly prophy-
laxis arm during A-LONG (3.59) [13]. Many subjects
previously treated episodically with rFVIIIFc switched
to a prophylactic regimen in the extension study, sug-
gesting that the prophylactic dosing options in
ASPIRE were suitable for patients who may have pre-
viously been unwilling or unable to commit to a pro-
phylactic regimen.
In the A-LONG and Kids A-LONG studies, the
median total weekly rFVIIIFc prophylactic dose was
comparable to the median prestudy total weekly FVIII
prophylactic dose, but with a reduced number of infu-
sions required per week [14,15]. In ASPIRE, subjects’
total weekly rFVIIIFc prophylactic dose generally did
not change or decreased relative to that at the end of
the parent study, and the majority of subjects main-
tained or further increased their dosing interval com-
pared with the parent study. These data suggest that
rFVIIIFc prophylaxis has the potential to offer greater
treatment flexibility than a conventional FVIII prod-
uct; rFVIIIFc might be administered more frequently
to maintain higher FVIII trough levels, if desired, or
with an extended dosing interval to reduce infusion
burden.
The efficacy of rFVIIIFc for the prevention and con-
trol of bleeding was maintained during the extension
study, with subjects in the prophylaxis groups exhibit-
ing low ABRs and the majority of subjects in all treat-
ment groups reporting high satisfaction with
resolution of bleeding episodes, consistent with what
was observed in A-LONG [13] and Kids A-LONG
[14]. In some cases, the bleeding rates observed in
ASPIRE, particularly for spontaneous joint bleeds,
were lower than those observed in the parent studies,
even when infusion intervals were lengthened. Addi-
tionally, in subjects entering the parent studies with
target joints, bleeding rates were low with rFVIIIFc
prophylaxis. These data suggest that rFVIIIFc prophy-
laxis is highly efficacious for the long-term treatment
of haemophilia A, including in patients with target
joints.
The ASPIRE protocol allowed for a high degree of
dosing flexibility across all treatment groups, and the
individualization of dosing regimens was designed to
create a setting that was generally reflective of real-
world practices. However, the allowance for subjects
to change treatment groups during the study made
direct comparisons between treatment groups difficult.
Other study limitations include the small number of
subjects in the weekly prophylaxis group, and in par-
ticular the lack of paediatric subjects in this group (as
dictated by the protocol). As there were no major sur-
geries in Kids A-LONG subjects during ASPIRE, data
on the use of rFVIIIFc in a surgical setting in subjects
aged <12 years are lacking. Analyses were limited to
the data available as of the interim data cut, and
many of the paediatric subjects had participated in
ASPIRE for <6 months. Although subjects >12 years
of age had significant exposure to rFVIIIFc in the par-
ent studies, longer term follow-up is needed in
patients ≤12 years of age. Additionally, exclusion of
subjects with history of an inhibitor makes it difficult
to determine if the lack of inhibitors observed in
ASPIRE would be applicable in a patient population
at high risk for inhibitor development; further study is
needed to characterize the immunogenicity of rFVIIIFc
in such patients.
In summary, the ASPIRE extension study represents
the first longer term clinical experience to date with a
prolonged half-life rFVIII therapy. Interim data from
the study provide further confirmation of the safety
and efficacy of rFVIIIFc prophylaxis in paediatric,
adolescent, and adult patients with severe haemophilia
A, and demonstrate maintenance of a low ABR with
extended prophylactic dosing intervals.
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